- Home
- THRD vs PBYI Comparison
THRD vs PBYI Comparison
Compare THRD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- PBYI
- Stock Information
- Founded
- THRD 2019
- PBYI 2010
- Country
- THRD United States
- PBYI United States
- Employees
- THRD N/A
- PBYI 185
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- THRD Health Care
- PBYI Health Care
- Exchange
- THRD Nasdaq
- PBYI Nasdaq
- Market Cap
- THRD 157.7M
- PBYI 147.8M
- IPO Year
- THRD 2022
- PBYI N/A
- Fundamental
- Price
- THRD $3.55
- PBYI $3.01
- Analyst Decision
- THRD Hold
- PBYI Strong Buy
- Analyst Count
- THRD 3
- PBYI 1
- Target Price
- THRD $5.00
- PBYI $7.00
- AVG Volume (30 Days)
- THRD 343.0K
- PBYI 372.2K
- Earning Date
- THRD 05-14-2025
- PBYI 05-01-2025
- Dividend Yield
- THRD N/A
- PBYI N/A
- EPS Growth
- THRD N/A
- PBYI 37.78
- EPS
- THRD N/A
- PBYI 0.62
- Revenue
- THRD N/A
- PBYI $230,468,000.00
- Revenue This Year
- THRD N/A
- PBYI N/A
- Revenue Next Year
- THRD N/A
- PBYI N/A
- P/E Ratio
- THRD N/A
- PBYI $4.85
- Revenue Growth
- THRD N/A
- PBYI N/A
- 52 Week Low
- THRD $3.18
- PBYI $2.23
- 52 Week High
- THRD $16.94
- PBYI $6.06
- Technical
- Relative Strength Index (RSI)
- THRD 42.90
- PBYI 42.30
- Support Level
- THRD $3.34
- PBYI $3.14
- Resistance Level
- THRD $3.68
- PBYI $3.18
- Average True Range (ATR)
- THRD 0.14
- PBYI 0.19
- MACD
- THRD 0.07
- PBYI -0.06
- Stochastic Oscillator
- THRD 62.86
- PBYI 17.81
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.